{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T11:01:57Z","timestamp":1781521317311,"version":"3.54.1"},"reference-count":42,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,4,1]],"date-time":"2026-04-01T00:00:00Z","timestamp":1775001600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","pathologyjournal.rcpa.edu.au","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pathology"],"published-print":{"date-parts":[[2026,4]]},"DOI":"10.1016\/j.pathol.2025.10.010","type":"journal-article","created":{"date-parts":[[2026,1,28]],"date-time":"2026-01-28T16:42:18Z","timestamp":1769618538000},"page":"266-275","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["The spectrum of clinical and histopathological features in patients undergoing liver biopsy for immune-checkpoint-inhibitor-associated hepatotoxicity: a 10-year multicentre experience"],"prefix":"10.1016","volume":"58","author":[{"ORCID":"https:\/\/orcid.org\/0009-0008-6144-7953","authenticated-orcid":false,"given":"Choon Ean","family":"Boon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9881-3023","authenticated-orcid":false,"given":"Preithy","family":"Uthamalingam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3314-1227","authenticated-orcid":false,"given":"Dilini","family":"Gunawardena","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3685-3166","authenticated-orcid":false,"given":"Tim","family":"Mitchell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bella","family":"Nguyen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4062-7839","authenticated-orcid":false,"given":"Willem Bastian","family":"de Boer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.pathol.2025.10.010_bib1","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41572-020-0160-6","article-title":"Immune-related adverse events of checkpoint inhibitors","volume":"6","author":"Ramos-Casals","year":"2020","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.pathol.2025.10.010_bib2","doi-asserted-by":"crossref","first-page":"5376","DOI":"10.3748\/wjg.v27.i32.5376","article-title":"Immune checkpoint inhibitor-related hepatotoxicity: a review","volume":"27","author":"Remash","year":"2021","journal-title":"World J Gastroenterol"},{"key":"10.1016\/j.pathol.2025.10.010_bib3","doi-asserted-by":"crossref","first-page":"2235","DOI":"10.1007\/s00432-022-04340-3","article-title":"Immune checkpoint inhibitor-induced hepatitis injury: risk factors, outcomes, and impact on survival","volume":"149","author":"Miah","year":"2023","journal-title":"J Cancer Res Clin Oncol"},{"key":"10.1016\/j.pathol.2025.10.010_bib5","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1634\/theoncologist.2018-0174","article-title":"Diagnosis and management of hepatitis in patients on checkpoint blockade","volume":"23","author":"Reynolds","year":"2018","journal-title":"Oncologist"},{"key":"10.1016\/j.pathol.2025.10.010_bib6","doi-asserted-by":"crossref","first-page":"1217","DOI":"10.1016\/j.annonc.2022.10.001","article-title":"Management of toxicities from immunotherapy: ESMO clinical practice guideline for diagnosis, treatment and follow-up","volume":"33","author":"Haanen","year":"2022","journal-title":"Ann Oncol"},{"key":"10.1016\/j.pathol.2025.10.010_bib7","doi-asserted-by":"crossref","first-page":"e15","DOI":"10.1097\/PAS.0000000000001730","article-title":"Histopathology of gastrointestinal immune-related adverse events: a practical review for the practicing pathologist","volume":"46","author":"Zhang","year":"2022","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2025.10.010_bib8","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/s41379-020-00653-1","article-title":"Liver biopsy findings in patients on immune checkpoint inhibitors","volume":"34","author":"Cohen","year":"2021","journal-title":"Mod Pathol"},{"key":"10.1016\/j.pathol.2025.10.010_bib9","doi-asserted-by":"crossref","first-page":"470","DOI":"10.1111\/his.14000","article-title":"Immune-related adverse reactions in the hepatobiliary system: second-generation check-point inhibitors highlight diverse histological changes","volume":"76","author":"Zen","year":"2020","journal-title":"Histopathology"},{"key":"10.1016\/j.pathol.2025.10.010_bib10","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/gastro\/goz044","article-title":"Histologic patterns of liver injury induced by anti-PD-1 therapy","volume":"8","author":"Zhang","year":"2020","journal-title":"Gastroenterol Rep (Oxf)"},{"key":"10.1016\/j.pathol.2025.10.010_bib11","doi-asserted-by":"crossref","first-page":"571","DOI":"10.5858\/arpa.2020-0070-RA","article-title":"Pathologic manifestations of gastrointestinal and hepatobiliary injury in immune checkpoint inhibitor therapy","volume":"145","author":"Patil","year":"2021","journal-title":"Arch Pathol Lab Med"},{"key":"10.1016\/j.pathol.2025.10.010_bib12","doi-asserted-by":"crossref","first-page":"e858","DOI":"10.1097\/MEG.0000000000002280","article-title":"Immune-related cholangitis induced by immune checkpoint inhibitors: a systematic review of clinical features and management","volume":"33","author":"Pi","year":"2021","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"10.1016\/j.pathol.2025.10.010_bib13","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000268","article-title":"Severe steroid-resistant anti-PD1 T-cell checkpoint inhibitor-induced hepatotoxicity driven by biliary injury","volume":"2","author":"Doherty","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.pathol.2025.10.010_bib14","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/liv.15340","article-title":"Immune checkpoint inhibitor-related cholangiopathy: novel clinicopathological description of a multi-centre cohort","volume":"43","author":"Berry","year":"2023","journal-title":"Liver Int"},{"key":"10.1016\/j.pathol.2025.10.010_bib15","doi-asserted-by":"crossref","first-page":"2717","DOI":"10.1002\/hep.30596","article-title":"Letter to the editor: is nodular regenerative hyperplasia an immune-mediated phenomenon?","volume":"69","author":"Had\u017ei\u0107","year":"2019","journal-title":"Hepatology"},{"key":"10.1016\/j.pathol.2025.10.010_bib16","doi-asserted-by":"crossref","first-page":"251","DOI":"10.14309\/ajg.0000000000000398","article-title":"Clinical characteristics and adverse impact of hepatotoxicity due to immune checkpoint inhibitors","volume":"15","author":"Miller","year":"2020","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.pathol.2025.10.010_bib17","doi-asserted-by":"crossref","first-page":"878","DOI":"10.14309\/ajg.0000000000001259","article-title":"ACG clinical guideline: diagnosis and management of idiosyncratic drug-induced liver injury","volume":"116","author":"Chalasani","year":"2021","journal-title":"Am J Gastroenterol"},{"key":"10.1016\/j.pathol.2025.10.010_bib18","series-title":"Origin of immune checkpoint inhibitors","author":"Bernard","year":"2022"},{"key":"10.1016\/j.pathol.2025.10.010_bib19","article-title":"Immune-mediated hepatitis induced by immune checkpoint inhibitors: current updates and future perspectives","volume":"13","author":"Liu","year":"2022","journal-title":"Front Pharmacol"},{"key":"10.1016\/j.pathol.2025.10.010_bib20","series-title":"Australian public assessment report for ipilimumab","year":"2011"},{"key":"10.1016\/j.pathol.2025.10.010_bib21","series-title":"Australian public assessment report for pembrolizumab (rch)","year":"2016"},{"key":"10.1016\/j.pathol.2025.10.010_bib22","series-title":"Australian public assessment report for nivolumab","year":"2016"},{"key":"10.1016\/j.pathol.2025.10.010_bib23","series-title":"Australian public assessment report for atezolizumab","year":"2018"},{"key":"10.1016\/j.pathol.2025.10.010_bib24","series-title":"Clinical and research information on drug-induced liver injury","year":"2022"},{"key":"10.1016\/j.pathol.2025.10.010_bib25","series-title":"Clinical and research information on drug-induced liver injury","year":"2022"},{"key":"10.1016\/j.pathol.2025.10.010_bib26","series-title":"Clinical and research information on drug-induced liver injury","year":"2022"},{"key":"10.1016\/j.pathol.2025.10.010_bib27","series-title":"Clinical and research information on drug-induced liver injury","year":"2022"},{"issue":"Suppl 2","key":"10.1016\/j.pathol.2025.10.010_bib28","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1136\/annrheumdis-2019-eular.2707","article-title":"Immune-related adverse events induced by cancer immunotherapies. Big data analysis of 13,051 cases (ImmunoCancer International Registry)","volume":"78","author":"Ramos-Casals","year":"2019","journal-title":"Ann Rheum"},{"key":"10.1016\/j.pathol.2025.10.010_bib29","article-title":"Incidence, risk factors and outcomes of checkpoint inhibitor-induced liver injury: a 10-year real-world retrospective cohort study","volume":"5","author":"Atallah","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.pathol.2025.10.010_bib30","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.907591","article-title":"Immune-mediated hepatitis during immune checkpoint inhibitor cancer immunotherapy: lessons from autoimmune hepatitis and liver immunology","volume":"13","author":"Hercun","year":"2022","journal-title":"Front Immunol"},{"key":"10.1016\/j.pathol.2025.10.010_bib31","doi-asserted-by":"crossref","first-page":"795","DOI":"10.3390\/cancers16040795","article-title":"The ABC of immune-mediated hepatitis during immunotherapy in patients with cancer: from pathogenesis to multidisciplinary management","volume":"16","author":"Lasagna","year":"2024","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.pathol.2025.10.010_bib32","article-title":"Clinical pattern of checkpoint inhibitor-induced liver injury in a multicentre cohort","volume":"5","author":"Hountondji","year":"2023","journal-title":"JHEP Rep"},{"key":"10.1016\/j.pathol.2025.10.010_bib33","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1016\/j.jhep.2018.01.033","article-title":"Characterization of liver injury induced by cancer immunotherapy using immune checkpoint inhibitors","volume":"68","author":"De Martin","year":"2018","journal-title":"J Hepatol"},{"key":"10.1016\/j.pathol.2025.10.010_bib34","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1097\/PAS.0000000000000453","article-title":"Ipilimumab-associated hepatitis: clinicopathologic characterization in a series of 11 cases","volume":"39","author":"Johncilla","year":"2015","journal-title":"Am J Surg Pathol"},{"key":"10.1016\/j.pathol.2025.10.010_bib35","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1016\/j.jhep.2020.10.035","article-title":"IL-17A\/F enable cholangiocytes to restrict T cell-driven experimental cholangitis by upregulating PD-L1 expression","volume":"74","author":"Stein","year":"2021","journal-title":"J Hepatol"},{"key":"10.1016\/j.pathol.2025.10.010_bib36","doi-asserted-by":"crossref","DOI":"10.1111\/liv.16097","article-title":"Role of liver biopsy in the management of idiosyncratic DILI","volume":"45","author":"Kleiner","year":"2025","journal-title":"Liver Int"},{"key":"10.1016\/j.pathol.2025.10.010_bib37","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1016\/j.cgh.2023.12.008","article-title":"Cholangitis induced by immune checkpoint inhibitors: analysis of pharmacovigilance data","volume":"22","author":"Meunier","year":"2024","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.pathol.2025.10.010_bib38","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000019013","article-title":"Safety and efficacy of immune checkpoint inhibitors in patients with HBV\/HCV infection and advanced-stage cancer: a systematic review","volume":"99","author":"Pu","year":"2020","journal-title":"Medicine"},{"key":"10.1016\/j.pathol.2025.10.010_bib39","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2023.1326078","article-title":"PD-1\/PD-L1 immune checkpoint therapy demonstrates favorable safety profile in patients with autoimmune and cholestatic liver disease","volume":"14","author":"Kocheise","year":"2024","journal-title":"Front Immunol"},{"key":"10.1016\/j.pathol.2025.10.010_bib40","doi-asserted-by":"crossref","first-page":"744","DOI":"10.1001\/jamaoncol.2021.0051","article-title":"Chronic immune-related adverse events following adjuvant anti-PD-1 therapy for high-risk resected melanoma","volume":"7","author":"Patrinely","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.pathol.2025.10.010_bib41","doi-asserted-by":"crossref","first-page":"2858","DOI":"10.3390\/cancers15102858","article-title":"Immune checkpoint inhibitors combined with targeted therapy: the recent advances and future potentials","volume":"15","author":"Li","year":"2023","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.pathol.2025.10.010_bib42","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1001\/jamaoncol.2021.4342","article-title":"Utility of liver biopsy in diagnosis and management of high-grade immune checkpoint inhibitor hepatitis in patients with cancer","volume":"7","author":"Li","year":"2021","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.pathol.2025.10.010_bib43","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/EDBK_100013","article-title":"Gastrointestinal and hepatic toxicities of checkpoint inhibitors: algorithms for management","volume":"38","author":"Grover","year":"2018","journal-title":"Am Soc Clin Oncol Educ Book"}],"container-title":["Pathology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003130252600351X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S003130252600351X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,19]],"date-time":"2026-03-19T20:12:33Z","timestamp":1773951153000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S003130252600351X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4]]},"references-count":42,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,4]]}},"alternative-id":["S003130252600351X"],"URL":"https:\/\/doi.org\/10.1016\/j.pathol.2025.10.010","relation":{},"ISSN":["0031-3025"],"issn-type":[{"value":"0031-3025","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The spectrum of clinical and histopathological features in patients undergoing liver biopsy for immune-checkpoint-inhibitor-associated hepatotoxicity: a 10-year multicentre experience","name":"articletitle","label":"Article Title"},{"value":"Pathology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pathol.2025.10.010","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Royal College of Pathologists of Australasia. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}